On Thursday, H.C. Wainwright lifted its price target on shares of Cingulate (NASDAQ: CING) to $20.00, a significant increase from the previous target of $8.00. The firm has maintained a Buy rating on ...
KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.
Cingulate Inc. reinstated the company's founder as CEO after a domestic battery case involving him was resolved.
TipRanks on MSN
Cingulate Inc reinstates Shane Schaffer as CEO
An announcement from Cingulate Inc ( ($CING) ) is now available. Cingulate Inc. announced that as of December 15, 2025, Shane Schaffer has been ...
Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...
KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug Filing KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING ...
Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback